{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-019671","form_type":"8-K","ticker":"COLL","cik":"0001267565","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2023-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.169605+00:00","generated_at":"2026-06-19T15:39:42.149578+00:00","sec_items":["1.01","2.03","3.02","8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Collegium prices $241.5M convertible notes offering, repurchases $117.4M of 2026 notes","bullets":["Priced $210M convertible notes offering, upsized to $241.5M with full exercise of initial purchasers' option.","Notes bear 2.875% interest, mature Feb 2029; initial conversion price $36.56/share, ~30% premium to $28.12.","Net proceeds estimated at $203.2M ($233.8M if greenshoe fully exercised) after discounts and expenses.","Used $140.1M to repurchase $117.4M of its 2.625% convertible notes due 2026.","Remainder for general corporate purposes including business development and capital allocation."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-019671","json":"https://secwatch.observer/filing/0001104659-23-019671.json","markdown":"https://secwatch.observer/filing/0001104659-23-019671.md","text":"https://secwatch.observer/filing/0001104659-23-019671.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1267565/000110465923019671/0001104659-23-019671-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1267565/000110465923019671/tm235915d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T15:39:42.149578+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b87a49929a45929831c2d558445ea4f30ed996a1","claim":"COLLEGIUM PHARMACEUTICAL, INC incurred convertible notes of $241,500,000 principal amount with The Bank of New York Mellon Trust Company, N.A. at 2.875% per annum maturing February 15, 2029.","evidence_excerpt":"On February 10, 2023, Collegium Pharmaceutical, Inc. (the “ Company ”) issued $241,500,000 principal amount of its 2.875% Convertible Senior Notes due 2029 (the “ Notes ”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465923019671/0001104659-23-019671-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$241,500,000 principal amount"},{"label":"Counterparty","value":"The Bank of New York Mellon Trust Company, N.A."},{"label":"Rate","value":"2.875% per annum"},{"label":"Maturity","value":"February 15, 2029"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"5e079cba06b28ee366cf7d1d846d930ff5ff5c85","claim":"COLLEGIUM PHARMACEUTICAL, INC entered into 2.875% Convertible Senior Notes due 2029 Indenture with The Bank of New York Mellon Trust Company, N.A. valued at $241,500,000 principal amount of 2.875% Convertible Senior Notes due 2029 (effective 2023-02-10).","evidence_excerpt":"On February 10, 2023, Collegium Pharmaceutical, Inc. (the “ Company ”) issued $241,500,000 principal amount of its 2.875% Convertible Senior Notes due 2029 (the “ Notes ”). The Notes were issued pursuant to, and are governed by, an indenture (the “ Indenture ”), dated as of February 10, 2023, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (the “ Trustee ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267565/000110465923019671/0001104659-23-019671-index.htm","confidence":0.98,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"The Bank of New York Mellon Trust Company, N.A."},{"label":"Value","value":"$241,500,000 principal amount of 2.875% Convertible Senior Notes due 2029"},{"label":"Effective","value":"2023-02-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}